Navigation Links
Carbapenem Drug Class Shows an Increase in Hospital Inpatient Courses in Europe
Date:11/6/2008

Just Over One-Third of All Carbapenem Courses Are Used as Documented/Confirmed Therapy, According To New Data from Arlington Medical

Resources

MALVERN, Pa., Nov. 6 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that in the January -- June 2008 time period, the carbapenem drug class in hospital inpatient courses in Europe has grown seven percent compared to the January -- June 2007 time period. These antibiotics are commonly used to treat lower respiratory infections, systemic infections, abdominal/pelvic infections and GI/biliary infections.

"Among carbapenem antibiotics Merck's Primaxin/Tienam (imipenem/cilastatin) has the largest share of courses (54 percent), followed by AstraZeneca's Merrem/Meronem (meropenem) (36 percent) and Merck's Invanz (ertapenem injectable) (10 percent)," stated Joyce Wedemeyer, product director at AMR. "These shares are consistent with our prior audit for the January -- June 2007 time period."

The newly released European edition of The Hospital Antibiotic Market Guide also finds that just over one-third of all carbapenem courses are used as documented/confirmed therapy. Inpatients treated with a carbapenem course in a documented/confirmed case are most commonly associated with escherichia coli (29 percent of documented courses), pseudomonas aeruginosa (20 percent), methicillin-sensitive staphylococcus aureus (9 percent) and enterococcus faecalis (8 percent).

Why Pharmaceutical Companies Need this Information

The Hospital Antibiotic Market Guide enables pharmaceutical companies to monitor patient shares, costs, infectious disease prevalence and the clinical use of antibiotics in acute care hospitals. In addition, pathogen-level details are available for those inpatient antibiotic drug courses associated with positive microbiological culture results.

About The Hospital Antibiotic Market Guide

The Hospital Antibiotic Market Guide is the industry's most comprehensive audit of inpatient antibiotic usage covering acute care hospitals in the United States, Italy, Germany, France, U.K. and Spain. The information in the audit is abstracted directly from hospital source documents from a panel of demographically representative acute care hospitals of all sizes, including transplant centers. The U.S. data is published twice a year and the European data is published once a year.

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
2. ADDA Kicks Off AD/HD Awareness Campaign with Four Regional Conferences Beginning Sept. 29 and Series of Fall Teleclasses
3. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
4. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
5. Theater Classes Help Docs Bedside Manners
6. Tarpinian: Misclassification is Theft
7. New class of RNA molecules may be important in human cancer
8. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
9. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
10. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
11. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... has selected HealthiPASS, an innovative patient - centric payment system, to expand its ... massive improvements in the patient financial experience. , “At Ogden Clinic, we ...
(Date:3/23/2017)... ... ... a simple and strong explanation of the God’s love. “More Corruption” is the creation of ... God to write a book about Him. , She says, “I’m fed up with mortals ... the Lord God. They have not walked in my shoes and I know they never ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, ... first issue of its companion print magazine. The new magazine, scheduled for release ... to information provided by board-certified doctors from across the country. , According to ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... Santa Cruz and Milpitas with a robust, ongoing community enrichment program, has announced ... a nonprofit organization which has provided for the critical needs of homeless families ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017  Ablation is the minimally invasive ... range of purposes, from cancerous or diseased tissue ... tissue in atrial fibrillation and others. The growing ... researchers to innovate and improvise existing ablation technologies ... device global market is expected to grow at ...
(Date:3/22/2017)... 22, 2017 TapImmune, Inc. ... the development of innovative peptide and gene-based immunotherapeutics ... today announced that it will participate in two ... Glynn Wilson , Chairman and CEO of ... business, clinical pipeline and partnering opportunities for its ...
(Date:3/22/2017)... March 22, 2017 Piramal Pharma ... (CDMO), held a special event to introduce the new ... Lexington, Kentucky . The inaugural event was ... Chairman Ajay Piramal, and Piramal Pharma Solutions CEO, ... ...
Breaking Medicine Technology: